LetterLetter
Trend in Industry Payments to Rheumatologists in the United States During the COVID-19 Pandemic Between 2013 and 2021
Anju Murayama, Sae Kamamoto, Kenichi Higuchi, Haruki Shigeta and Akihiko Ozaki
The Journal of Rheumatology October 2022, jrheum.220512; DOI: https://doi.org/10.3899/jrheum.220512
Anju Murayama
Medical Governance Research Institute, Minato-ku, Tokyo; Tohoku University School of Medicine, Sendai, Miyagi; Hamamatsu University School of Medicine, Hamamatsu, Shizuoka; Department of Breast and Thyroid Surgery, Jyoban Hospital, Iwaki, Fukushima, Japan. AO received personal fees from Medical Network Systems, a dispensing pharmacy, outside the scope of the submitted work. Regarding nonfinancial conflicts of interest among the study authors, the authors are engaged in ongoing research examining financial and nonfinancial conflicts of interest among healthcare professionals and pharmaceutical companies in Japan and the US. Address correspondence to Dr. A. Murayama, Medical Governance Research Institute, Minato-ku, Tokyo, 1087505, Japan. Email address: ange21tera@gmail.com.
Sae Kamamoto
Medical Governance Research Institute, Minato-ku, Tokyo; Tohoku University School of Medicine, Sendai, Miyagi; Hamamatsu University School of Medicine, Hamamatsu, Shizuoka; Department of Breast and Thyroid Surgery, Jyoban Hospital, Iwaki, Fukushima, Japan. AO received personal fees from Medical Network Systems, a dispensing pharmacy, outside the scope of the submitted work. Regarding nonfinancial conflicts of interest among the study authors, the authors are engaged in ongoing research examining financial and nonfinancial conflicts of interest among healthcare professionals and pharmaceutical companies in Japan and the US. Address correspondence to Dr. A. Murayama, Medical Governance Research Institute, Minato-ku, Tokyo, 1087505, Japan. Email address: ange21tera@gmail.com.
Kenichi Higuchi
Medical Governance Research Institute, Minato-ku, Tokyo; Tohoku University School of Medicine, Sendai, Miyagi; Hamamatsu University School of Medicine, Hamamatsu, Shizuoka; Department of Breast and Thyroid Surgery, Jyoban Hospital, Iwaki, Fukushima, Japan. AO received personal fees from Medical Network Systems, a dispensing pharmacy, outside the scope of the submitted work. Regarding nonfinancial conflicts of interest among the study authors, the authors are engaged in ongoing research examining financial and nonfinancial conflicts of interest among healthcare professionals and pharmaceutical companies in Japan and the US. Address correspondence to Dr. A. Murayama, Medical Governance Research Institute, Minato-ku, Tokyo, 1087505, Japan. Email address: ange21tera@gmail.com.
Haruki Shigeta
Medical Governance Research Institute, Minato-ku, Tokyo; Tohoku University School of Medicine, Sendai, Miyagi; Hamamatsu University School of Medicine, Hamamatsu, Shizuoka; Department of Breast and Thyroid Surgery, Jyoban Hospital, Iwaki, Fukushima, Japan. AO received personal fees from Medical Network Systems, a dispensing pharmacy, outside the scope of the submitted work. Regarding nonfinancial conflicts of interest among the study authors, the authors are engaged in ongoing research examining financial and nonfinancial conflicts of interest among healthcare professionals and pharmaceutical companies in Japan and the US. Address correspondence to Dr. A. Murayama, Medical Governance Research Institute, Minato-ku, Tokyo, 1087505, Japan. Email address: ange21tera@gmail.com.
Akihiko Ozaki
Medical Governance Research Institute, Minato-ku, Tokyo; Tohoku University School of Medicine, Sendai, Miyagi; Hamamatsu University School of Medicine, Hamamatsu, Shizuoka; Department of Breast and Thyroid Surgery, Jyoban Hospital, Iwaki, Fukushima, Japan. AO received personal fees from Medical Network Systems, a dispensing pharmacy, outside the scope of the submitted work. Regarding nonfinancial conflicts of interest among the study authors, the authors are engaged in ongoing research examining financial and nonfinancial conflicts of interest among healthcare professionals and pharmaceutical companies in Japan and the US. Address correspondence to Dr. A. Murayama, Medical Governance Research Institute, Minato-ku, Tokyo, 1087505, Japan. Email address: ange21tera@gmail.com.

Abstract
The Open Payments Database (OPD), the legally binding database of payments made by pharmaceutical companies and device manufacturers to all physicians,1 was launched in 2013 in the United States, in order to improve transparency in the financial relationship between healthcare professionals and industry. Meanwhile, a large number of the general public and physicians were not aware of the OPD2,3 and there has been no reducing trend among rheumatologists so far.4
In this issue
The Journal of Rheumatology
Vol. 50, Issue 1
1 Jan 2023
Trend in Industry Payments to Rheumatologists in the United States During the COVID-19 Pandemic Between 2013 and 2021
Anju Murayama, Sae Kamamoto, Kenichi Higuchi, Haruki Shigeta, Akihiko Ozaki
The Journal of Rheumatology Oct 2022, jrheum.220512; DOI: 10.3899/jrheum.220512